GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| GRAL | GRAIL, Inc. | 2026-04-02 18:30:29 | 54.99 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GRAL | 0001699031 | GRAIL, Inc. | US3847471014 | 2549009XSNESW3VE8024 | 863673636 | Nasdaq | 8071 | Services-Medical Laboratories | 1231 | DE | 1525 O'BRIEN DRIVE | MENLO PARK | CA | 94025 | UNITED STATES | US | (833) 694-2553 | 1525 O'BRIEN DRIVE, MENLO PARK, CA, 94025 | 1525 O'BRIEN DRIVE, MENLO PARK, CA, 94025 | GRAIL, LLC | Biotechnology | 2015 | Bob Ragusa | 1,000 | https://grail.com | 1,900,000,000 | 40,331,360 | 41,020,255 | GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021. | 2026-04-02 16:55:50 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 1,900,000,000 | 1,422,800,000 | 298.1559 | 41,020,255 | 7,125,009 | 21.0207 |
| 2024 | 477,200,000 | 477,200,000 | 100 | 33,895,246 | 33,895,246 | 100 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Robert Ragusa | Chief Executive Officer | 2024 | 785,000 | 0 | 6,069,206 | 714,350 | 40,351 | 7,608,907 |
| Aaron Freidin | Chief Financial Officer | 2024 | 560,000 | 0 | 2,875,021 | 254,800 | 3,000 | 3,692,821 |
| Josh Ofman | President | 2024 | 655,000 | 0 | 4,765,435 | 298,025 | 87,795 | 5,806,255 |
| Robert Ragusa | Chief Executive Officer | 2023 | 779,615 | 0 | 8,400,000 | 678,946 | 19,660 | 9,878,221 |
| Aaron Freidin | Chief Financial Officer | 2023 | 556,154 | 0 | 2,800,000 | 242,170 | 3,000 | 3,601,324 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 910 |
| 2024 | 1,000 |
| Fiscal Year | 2025 | 2024 |
|---|---|---|
| Revenue | 147,172,000 | 125,595,000 |
| Cost Of Revenue | 73,251,000 | 63,284,000 |
| Gross Profit | — | — |
| Research And Development Expenses | 195,794,000 | 322,380,000 |
| General And Administrative Expenses | 159,103,000 | 213,862,000 |
| Operating Expenses | 709,335,000 | 2,314,753,000 |
| Operating Income | -562,163,000 | -2,189,158,000 |
| Net Income | -408,351,000 | -2,027,005,000 |
| Earnings Per Share Basic | -11.11 | -63.54 |
| Earnings Per Share Diluted | -11.11 | -63.54 |
| Weighted Average Shares Outstanding Basic | 36,753,751 | 31,901,259 |
| Weighted Average Shares Outstanding Diluted | 36,753,751 | 31,901,259 |
| Fiscal Year | 2025 | 2024 |
|---|---|---|
| Cash And Cash Equivalents | 249,727,000 | 214,234,000 |
| Marketable Securities Current | — | — |
| Accounts Receivable | 18,295,000 | 20,312,000 |
| Inventories | — | — |
| Non Trade Receivables | 300,000 | 4,329,000 |
| Other Assets Current | — | 77,000 |
| Total Assets Current | 953,849,000 | 819,861,000 |
| Marketable Securities Non Current | — | — |
| Property Plant And Equipment | 51,813,000 | 69,061,000 |
| Other Assets Non Current | 6,753,000 | 7,773,000 |
| Total Assets Non Current | 1,968,166,000 | 2,163,446,000 |
| Total Assets | 2,922,015,000 | 2,983,307,000 |
| Accounts Payable | 2,083,000 | 4,844,000 |
| Deferred Revenue | — | — |
| Short Term Debt | — | — |
| Other Liabilities Current | 1,927,000 | 1,580,000 |
| Total Liabilities Current | 79,670,000 | 76,925,000 |
| Long Term Debt | — | — |
| Other Liabilities Non Current | 2,752,000 | 2,236,000 |
| Total Liabilities Non Current | 264,483,000 | 402,977,000 |
| Total Liabilities | 344,153,000 | 479,902,000 |
| Common Stock | 40,000 | 34,000 |
| Retained Earnings | -10,211,681,000 | -9,803,330,000 |
| Accumulated Other Comprehensive Income | 2,655,000 | 1,451,000 |
| Total Shareholders Equity | 2,577,862,000 | 2,503,405,000 |
| Fiscal Year | 2025 | 2024 |
|---|---|---|
| Depreciation And Amortization | 18,010,000 | 19,723,000 |
| Share Based Compensation Expense | 58,283,000 | 86,084,000 |
| Other Non Cash Income Expense | -1,347,000 | -276,000 |
| Change In Accounts Receivable | -1,685,000 | 3,370,000 |
| Change In Inventories | — | — |
| Change In Non Trade Receivables | — | — |
| Change In Other Assets | — | — |
| Change In Accounts Payable | -2,733,000 | -14,635,000 |
| Change In Other Liabilities | — | — |
| Cash From Operating Activities | -299,007,000 | -577,156,000 |
| Purchases Of Marketable Securities | 1,308,340,000 | 545,803,000 |
| Sales Of Marketable Securities | — | — |
| Acquisition Of Property Plant And Equipment | 909,000 | 5,208,000 |
| Acquisition Of Business | — | — |
| Other Investing Activities | — | — |
| Cash From Investing Activities | -85,049,000 | -551,011,000 |
| Tax Withholding For Share Based Compensation | 0 | 0 |
| Payments Of Dividends | — | — |
| Issuance Of Common Stock | 4,525,000 | — |
| Repurchase Of Common Stock | — | — |
| Issuance Of Long Term Debt | — | — |
| Repayment Of Long Term Debt | — | — |
| Other Financing Activities | — | — |
| Cash From Financing Activities | 423,321,000 | 1,244,300,000 |
| Change In Cash | 39,118,000 | 116,071,000 |
| Cash At End Of Period | 249,727,000 | 214,234,000 |
| Income Taxes Paid | 1,131,000 | — |
| Interest Paid | — | — |
| Fiscal Year | 2025 |
|---|---|
| Earnings Per Share | -11.11 |
| Price To Earnings Ratio | -7.7039 |
| Earnings Growth Rate | -82.515 |
| Price Earnings To Growth Ratio | 0.0934 |
| Book Value Per Share | 70.1387 |
| Price To Book Ratio | 1.2203 |
| Ebitda | -389,210,000 |
| Enterprise Value | — |
| Dividend Yield | — |
| Dividend Payout Ratio | — |
| Debt To Equity Ratio | — |
| Capital Expenditures | 762,000 |
| Free Cash Flow | -299,769,000 |
| Return On Equity | -0.1584 |
| One Year Beta | 2.3882 |
| Three Year Beta | 2.1779 |
| Five Year Beta | 2.1779 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| RAGUSA ROBERT P | Director, Chief Executive Officer | 2026-03-09 | 7,203 | D | 642,342 |
| RAGUSA ROBERT P | Director, Chief Executive Officer | 2026-03-09 | 258 | D | 642,084 |
| Ofman Joshua J. | President | 2026-03-09 | 2,836 | D | 432,982 |
| Ofman Joshua J. | President | 2026-03-09 | 101 | D | 432,881 |
| Freidin Aaron | Chief Financial Officer | 2026-03-09 | 2,407 | D | 306,560 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Ares Financial Consulting, LLC | 2026-03-31 | 107 | 2 | 53.5 |
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 410,832 | 4,800 | 85.59 |
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 45,960,632 | 536,986 | 85.59 |
| Rockefeller Capital Management L.P. | 2025-12-31 | 5,869,506 | 68,577 | 85.59 |
| Osbon Capital Management LLC | 2025-12-31 | 50,903 | 595 | 85.5513 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Direxion Shares ETF Trust | 2026-01-31 | Direxion Daily S&P Biotech Bull 3X ETF | LABU | 40,655 | 3,976,872.1 | 0.69 |
| Global X Funds | 2026-01-31 | Global X Russell 2000 ETF | RSSL | 15,864 | 1,551,816.48 | 0.112 |
| Pacer Funds Trust | 2026-01-31 | Pacer WealthShield ETF | PWS | 817 | 79,918.94 | 0.2543 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-01-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 118,023 | 11,545,009.86 | 0.4316 |
| PRIMECAP Odyssey Funds | 2026-01-31 | PRIMECAP Odyssey Aggressive Growth Fund | POAGX | 1,308,891 | 128,035,717.62 | 1.8541 |